Sun's buyout of Ranbaxy gets India's approval

India's high court has waived a waiting period for Sun Pharmaceutical to complete its $4 billion acquisition of Ranbaxy Laboratories. The merger is expected to be completed soon, which will set into motion Sun's pledge to reform manufacturing at Ranbaxy. Four of Ranbaxy's FDA-approved manufacturing facilities in India are banned from shipping to the U.S. market because of data integrity and quality issues. Story | More

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.